Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 million TARRYTOWN, N.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results